{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:52:05Z","timestamp":1790790725546,"version":"4.1.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus (SLE)-associated thrombotic microangiopathy with features of atypical hemolytic uremic syndrome (aHUS) is a rare but life-threatening complication. Early recognition is challenging because of its overlapping clinical manifestations with other thrombotic microangiopathies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>\n                      A 49-year-old man with SLE presented with anemia, thrombocytopenia, and multi-system involvement. Despite initial immunosuppressive therapy, his hematologic parameters progressively deteriorated, with hemoglobin decreasing to 89\u2009g\/L and the platelet count to 54\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Laboratory investigations demonstrated elevated lactate dehydrogenase (501 U\/L) and markedly increased soluble complement membrane attack complex (sC5b-9, &gt;1790\u2009ng\/mL). ADAMTS13 activity was normal (75.41%), excluding thrombotic thrombocytopenic purpura. Based on the clinical and laboratory findings, the patient was diagnosed with SLE-associated aHUS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Following the diagnosis, the patient received eculizumab, a monoclonal antibody targeting complement component C5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>\n                      Within 6 days of eculizumab treatment, hemoglobin increased to 102\u2009g\/L, and the platelet count recovered to 108\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L, indicating a rapid hematologic response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case highlights that aHUS can occur as a severe complication of SLE, even in male patients. Complement-mediated thrombotic microangiopathy may coexist with and be triggered by immune hemolysis in SLE. Early recognition and prompt complement inhibition with eculizumab can produce an ultra-rapid hematologic response and may be critical for improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046412","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:01:36Z","timestamp":1784322096000},"page":"e46412","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Systemic lupus erythematosus complicated by thrombotic microangiopathy with atypical HUS features: A case report"],"prefix":"10.1097","volume":"105","author":[{"given":"Yuting","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Second People\u2019s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2004-8036","authenticated-orcid":false,"given":"Jinjian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second People\u2019s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12882-020-01888-5","article-title":"A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.","volume":"21","author":"Wright","year":"2020","journal-title":"BMC Nephrol"},{"key":"R2-20260902","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ekir.2025.04.022","article-title":"Systematic review of the outcomes and prognostic factors of patients with systemic lupus erythematosus-associated thrombotic microangiopathy.","volume":"10","author":"Gai","year":"2025","journal-title":"Kidney Int Rep"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","article-title":"The immunology of systemic lupus erythematosus.","volume":"25","author":"Tsokos","year":"2024","journal-title":"Nat Immunol"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.kint.2019.01.043","article-title":"Secondary atypical hemolytic uremic syndromes in the era of complement blockade.","volume":"95","author":"Praga","year":"2019","journal-title":"Kidney Int"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.RV17026","article-title":"Pathogenesis of atypical hemolytic uremic syndrome.","volume":"26","author":"Yoshida","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"151436","DOI":"10.1016\/j.semnephrol.2023.151436","article-title":"HUS and TTP: traversing the disease and the age spectrum.","volume":"43","author":"Donadelli","year":"2024","journal-title":"Semin Nephrol"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling Ariadne\u2019s thread into the labyrinth of complement therapeutics.","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation.","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature.","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s00296-024-05558-9","article-title":"Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature.","volume":"44","author":"Smith","year":"2024","journal-title":"Rheumatol Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:00:16Z","timestamp":1788332416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":12,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046412","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2025-08-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}